共 127 条
[1]
Singh JA(2016)2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Arthritis Care Res 68 1-25
[2]
Saag KG(2017)Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study Ann Rheum Dis 76 88-95
[3]
Bridges SL(2016)Baricitinib in patients with refractory rheumatoid arthritis N Engl J Med 374 1243-1252
[4]
Akl EA(2010)The impact of rheumatoid arthritis and treatment on patients' lives Clin Exp Rheumatol 28 S32-40
[5]
Bannuru RR(2015)Patient reported outcomes in rheumatoid arthritis clinical trials Curr Rheumatol Rep 17 28-700
[6]
Sullivan MC(2019)Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation Trials 20 182-560
[7]
Dougados M(2017)Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis RMD Open 3 e000410-819
[8]
van der Heijde D(2015)Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis RMD Open 1 e000019-793
[9]
Chen YC(2017)Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON) Ann Rheum Dis 76 694-145
[10]
Greenwald M(2019)Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT Arthritis Res Ther 21 272-1487